Drug Database
MF

MF-59 (MF59)

✓ Approved

Novartis AG · Small Molecule · Small Molecule

What is MF-59?

MF-59 is a small molecule developed by Novartis AG. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesMF59
CompanyNovartis AG
Drug ClassSmall Molecule
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Therapeutic Indications

MF-59 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedCirculation2026-08-30

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease Among Adults Aged 20 to 100 Years.

Jeevanathan Janeni J, Thomas Peter E PE, Kamstrup Pia R PR, Nordestgaard Børge G BG

High lipoprotein(a) is considered a causal risk factor for atherosclerotic cardiovascular diseases (ASCVD); however, whether the association between lipoprotein(a) and ASCVD is different among older individuals (defined as 70-100 years of age) compared with younger individuals is unclear. We evaluated differences in risk of ASCVD associated with high lipoprotein(a) stratified by age and sex. We included 57 899 women and 45 442 men aged 20 to 100 years from the Copenhagen General Population Study, of which 18 322 (18%) were aged 70 to 100 years. Age-stratified incidence rates and hazard ratios for ASCVD were estimated. Secondary analyses were additionally stratified by sex. During a median follow-up of 12.5 years (maximum, 19.1), 9091 individuals were diagnosed with ASCVD. ASCVD incidence increase per 50 mg/dL (105 nmol/L) higher lipoprotein(a) were 0.3 per 1000 person-years (95% CI, 0.2-0.4) for age 20 to 49 years, 0.8 (0.6-0.9) for age 50 to 59 years, 1.5 (1.2-1.7) for age 60 to 69 years, 2.7 (2.2-3.2) for age 70 to 79 years, and 4.5 per 1000 person-years (3.7-5.4) for age 80 to 100 years. For lipoprotein(a) of 70 to 89 mg/dL (148-190 nmol/L), such incidence increases were 2.7 for age 20 to 49 years, 7.1 for age 50 to 59 years, 13.3 for age 60 to 69 years, 24.4 for age 70 to 79 years, and 40.9 for age 80 to 100 years. Corresponding values for lipoprotein(a) of 90 to 426 mg/dL (191-924 nmol/L) were 3.2, 8.3, 15.6, 28.7, and 48, respectively. The above results were similar in women and men, but with the highest incidence increases in men. Hazard ratios per 50 mg/dL higher lipoprotein(a) were similar across all age groups and sexes, ranging from 1.12 to 1.18 (Pinteraction: by age=0.48; by sex=0.74). In a contemporary primary prevention cohort, the relative risk increase of ASCVD with higher lipoprotein(a) levels was similar for individuals aged older (aged 70-100 years) and younger individuals, with the highest absolute risk in this older age group.

PMID 42669287
Read full article →
PubMedBiodiversity data journal2026-08-30

A Darwin Core dataset of scorpions (Arachnida, Scorpiones) from the Royal Belgian Institute of Natural Sciences (RBINS) Collections.

Durante Fabiola F, Prendini Lorenzo L, Pizzolotto Roberto R, Wérenne Gladys G et al.

This data paper details the publication of a dataset derived from the scorpion (Order Scorpiones C.L. Koch, 1850) collections preserved at the Royal Belgian Institute of Natural Sciences (RBINS), Brussels. The dataset includes all 3,652 specimens mostly identified to genus or species level during a recent re-evaluation. To maximise accessibility and interoperability, the entire dataset was fully standardised using the Darwin Core (DwC) standard and published as open data. The published dataset comprises a significant collection of records, encompassing eleven families, 56 genera and 117 species of scorpions. Geographically, the specimens originate from a wide range of locations, in 59 countries. The records within this dataset span a substantial chronological period, with collection dates ranging from 1872 to 2023. Most of the specimens were collected during expeditions led by researchers of RBINS. The mobilisation and standardisation of this rich historical collection provide a valuable resource for global biodiversity informatics, supporting crucial research in taxonomy, ecology and biogeography of the order Scorpiones.

PMID 42668906
Read full article →
PubMedCarbohydrate research2026-08-30

Chitosan-based Bi-nanocomposites for oral drug overdose remediation: A critical review of polysaccharide properties, adsorption mechanisms, and clinical translation pathways.

Egbeme Lucky E LE, Oyedeko Kamilu F KF, Elehinafe Francis B FB, Akinyemi Peter O PO et al.

Chitosan, a pH-sensitive cationic biopolymer possessing reactive amino groups (pKa 6.3), good biocompatibility, and functionalizability, makes an excellent adsorbent for biomedical application. Its combination with water hyacinth activated carbon through cross-linking provides synergistic adsorption that could be used in the treatment of drug overdose in oral medication. A systematic literature of Web of science, Scopus, PubMed and Google Scholar between January 2000 to April 2025, consisting of 59 original research papers and 41 non research papers. In this review, synthesis methods maintaining chitosan functional groups, adsorption mechanisms including electrostatic interactions, hydrogen bonding, hydrophobic effects, pore diffusion mechanism, relationship between structure and properties of nanocomposites, and their comparative environmental and biomedical performances will be discussed with the emphasis on challenges and translational strategies including in vitro physiological studies. The proposed review for the first time comprehensively discusses the field related to detoxification therapy and is distinct from other environment-oriented reviews.

PMID 42669280
Read full article →
PubMedClinical medicine insights. Case reports2026-08-30

Plasmacytomas in Extramedullary Manifestation of Multiple Myeloma: A Case Report.

Hmayed Jawad J, Fadel Doha D, Albayeh Anthony A, Jreij Chris C et al.

Extramedullary plasmacytomas are an uncommon manifestation of multiple myeloma (MM) and may involve a wide range of soft-tissue sites. Superficial involvement of the back is particularly rare and may be mistaken for benign soft-tissue lesions. We report the case of a 59-year-old man with MM diagnosed in April 2024 who was treated with four cycles of bortezomib, cyclophosphamide, and dexamethasone (VCD), achieving remission with disappearance of serum and urine M-protein on immunofixation. In October 2025, the disease relapsed, with early progression despite treatment with daratumumab, prompting initiation of teclistamab therapy. During the course of his disease, he developed two progressively enlarging, painless indurations over the left upper and lower back. Ultrasound demonstrated well-circumscribed heterogeneous hypoechoic subcutaneous masses with internal arterial vascularity on Doppler imaging. Ultrasound-guided core biopsy revealed diffuse infiltration by monoclonal plasma cells expressing CD138 with lambda light-chain restriction, confirming secondary extramedullary plasmacytoma. This case highlights the importance of considering extramedullary plasmacytoma in the differential diagnosis of new superficial soft-tissue masses in patients with MM and underscores the complementary role of ultrasound and histopathological examination in establishing the diagnosis.

PMID 42668685
Read full article →
PubMedCureus2026-08-30

Sequential Immune-Mediated Extrahepatic Complications of Hepatitis E Virus: A Case Report.

Padarabinda Tripathy Krishna K, Mishra Subhashree S, Laxman Virani A VA, Hima Varsha Palle Sree PS et al.

Hepatitis E virus (HEV) infection is classically described as causing self-limiting acute hepatitis. However, it is increasingly being recognised for a wide spectrum of immune-mediated extrahepatic complications involving the haematological, neurological, renal and pancreatic systems. These manifestations are more commonly seen as isolated presentations in individual patients. We report a 59-year-old man with serologically confirmed acute hepatitis E, in whom alternative infectious, autoimmune, and malignant etiologies were excluded, who developed three distinct immune-mediated complications in temporal sequence during a single hospital admission: autoimmune haemolytic anaemia (AIHA) at presentation, secondary haemophagocytic lymphohistiocytosis (HLH) within one week, and Guillain-Barré syndrome (GBS) on day 17. The chronological evolution of these complications suggested a progressive triphasic immune-mediated response following acute HEV infection. Each complication was diagnosed using established criteria and managed with targeted therapy-corticosteroids and supportive care for AIHA; etoposide, escalated dexamethasone, and cyclosporin for HLH; and intravenous immunoglobulin for GBS. The sequential development from early autoantibody-mediated haemolysis to hyperinflammatory macrophage activation and subsequent delayed post-infectious neuroimmune involvement reflects evolving immune dysregulation rather than coincident multisystem disease. The patient achieved complete clinical and biochemical recovery on follow-up. Sequential occurrence of AIHA, HLH, and GBS following acute HEV infection within a single hospital admission is rarely described. The case underscores the importance of maintaining a high index of suspicion for evolving extrahepatic immune-mediated complications in patients with acute HEV infection.

PMID 42668655
Read full article →
PubMedScandinavian journal of public health2026-08-30

Classification of type 1 diabetes and type 2 diabetes based on administrative registry data: a nationwide study from Norway.

Ruiz Paz Lopez-Doriga PL, Stene Lars C LC, Løvaas Karianne Fjeld KF, Ueland Grethe Åstrøm GÅ et al.

Type 1 diabetes (T1D) and type 2 diabetes (T2D) differ in health care needs. Precise prevalence estimates by type are important for health care planning. This validation study used Norwegian health registry data to develop a T1D/T2D classification method, using the Norwegian Diabetes Register for Adults (NDR-A) as reference standard. Our study population consisted of all individuals 18 years and older residing in Norway in 2022 (N = 4,315,563). We used Cohen's kappa to assess agreement between the classification method and the NDR-A. The established classification method had three key steps: (a) T1D, based on insulin use and specialist health care T1D diagnoses, (b) T2D, based on specialist and primary health care T2D, and (c) T1D, based on primary health care T1D and insulin use, and no T2D. The overall agreement with NDR-A diagnosis was 95.2% for T1D and 97.6% for T2D. For T1D, agreement was 97% or higher in age-groups 18-39 and 40-59, 87.6% for those aged 60-79 and 69.4% for individuals older than 80. For T2D, the agreement was 97% or higher for age-groups 40 and above, and 92.1% for those aged 18-39. Applying the classification method to total population data showed that, in 2022, among 4,315,563 individuals aged 18 and older living in Norway, 31,264 had T1D (0.72%) and 239,120 had T2D (5.5%). Our registry-based classification agreed well with the NDR-A, implying that administrative health registry data are suitable in epidemiological and health services studies of T1D and T2D.

PMID 42668388
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about MF-59